N-Boc-2-哌啶乙酸 | 149518-50-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-Boc-2-哌啶乙酸
• 中文别名: 1-叔丁氧羰基-2-哌啶乙酸；1-Boc-哌啶-2-乙酸
• 英文名称: 2-[2-N-(tert-butoxycarbonyl)piperidyl]acetic acid
• 英文别名: 2-(1-(tert-butoxycarbonyl)-2-piperidinyl)acetic acid；2-(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid；[1-(tert-butoxycarbonyl)piperidin-2-yl]acetic acid；[1-(tert-butoxycarbonyl)piperidine-2-yl]acetic acid；2-carboxymethyl-piperidine-1-carboxylic acid tert-butyl ester；2-(N-tert.butoxycarbonylpiperidine)acetic acid；1-Boc-2-piperidineacetic acid；2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-2-yl]acetic acid
• CAS: 149518-50-3
• 化学式: C₁₂H₂₁NO₄
• 分子量: 243.303
• InChiKey: CKAXJDBTNNEENW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Boc-2-piperidineacetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-2-piperidineacetic acid
CAS number: 149518-50-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H21NO4
Molecular weight: 243.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-Boc-2-哌啶乙酸 在 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 四溴化碳 、 N-[(2,4-二氯苯氧基)-甲氧基硫代膦酰]丙-2-胺 、 四丁基氟化铵 、 lithium 、 对甲苯磺酸 、 乙二胺 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 417.0h， 生成 (+/-)-aloperine
  参考文献：
  名称：

  Concise Total Synthesis of (±)-Aloperine and 6-epi-Aloperine

  摘要：

  Total synthesis of aloperine and 6-epi-aloperine is reported. The crucial steps of the synthetic strategy are an aza-annulation reaction and an intermolecular Diels-Alder reaction. The synthetic plan proceeds from commercially available piperidine-2-ethanol.

  DOI：

  10.1021/ol0263144
• 作为产物：
  描述：

  2-哌啶乙酸乙酯 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 N-Boc-2-哌啶乙酸
  参考文献：
  名称：

  Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof

  摘要：

  本文提供了融合咪唑基化合物，其合成方法以及使用方法。本文提供的化合物可用于治疗、预防和/或管理各种疾病，包括但不限于神经系统疾病和代谢性疾病。本文提供的化合物抑制组胺H3受体的活性，并调节各种神经递质的释放，例如组胺、乙酰胆碱、去甲肾上腺素和多巴胺（例如在突触处）。本文还提供了含有这些化合物的药物组合物及其使用方法。

  公开号：

  US20110065694A1

文献信息

• 吲哚-2-酮衍生物及其制备方法与用途
  申请人：北京志健金瑞生物医药科技有限公司

  公开号：CN111285872B

  公开（公告）日：2022-05-17

  本发明属于医药领域，具体涉及一种吲哚‑2‑酮衍生物及其制备方法与用途。本发明提供下式(I)所示的化合物、其立体异构体、消旋体、互变异构体、同位素标记物、氮氧化物、多晶型物、前药或其药学上可接受的盐。本发明的化合物可较好作用于对STK25靶点具有抑制作用，因此可以对与STK25相关的疾病或病症进行抑制治疗。而且，本发明化合物的制备方法简单，反应条件温和，产品收率高，适于工业化生产。
• Substituted Spiroamine Compounds
  申请人：REICH Melanie

  公开号：US20100113417A1

  公开（公告）日：2010-05-06

  Substituted spiroamine compounds corresponding to the formula (I) In which m, n, o, p, Q, r, s, t, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6a , R 6b , R 7 , R 8 , R 9 , R 10 and R 11 have defined meanings; a process for the preparation of such compounds, pharmaceutical compositions containing such compounds and the use of substituted spiroamines for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin 1 receptor.

  将符合以下公式（I）的取代螺胺化合物 其中m、n、o、p、Q、r、s、t、R1、R2、R3、R4a、R4b、R5a、R5b、R6a、R6b、R7、R8、R9、R10和R11具有定义的含义；一种制备这种化合物的方法，含有这种化合物的药物组合物以及利用取代螺胺对布雷金肽1受体介导的疼痛和/或其他病症进行治疗或抑制。
• Substituted Sulfonamide Compounds
  申请人：Oberboersch Stefan

  公开号：US20090264400A1

  公开（公告）日：2009-10-22

  Substituted sulfonamide compounds corresponding to formula I: processes for the preparation thereof, pharmaceutical compositions containing these compounds, and the use of such substituted sulfonamide compounds in pharmaceutical compositions for the treatment and/or inhibition of pain and other conditions at least partly mediated by the bradykinin 1 receptor.

  将与式I相对应的磺胺基取代化合物：其制备方法，含有这些化合物的药物组合物，以及在药物组合物中使用这些磺胺基取代化合物治疗和/或抑制至少部分由激肽酶1受体介导的疼痛和其他病症的用途。
• INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS
  申请人：ZHANG Xuqing

  公开号：US20110263559A1

  公开（公告）日：2011-10-27

  The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.

  本发明涉及替代吲唑化合物，这些化合物的药物组合物以及它们的使用方法。本发明的化合物是酮己糖激酶（KHK）抑制剂，可用于治疗或改善由KHK介导的代谢紊乱和/或疾病，如肥胖、Ⅱ型糖尿病和X型代谢综合征。
• Complex-Induced Proximity Effects:  The Effect of Varying Directing-Group Orientation on Carbamate-Directed Lithiation Reactions
  作者：Kathleen M. Bertini Gross、Peter Beak

  DOI：10.1021/ja002662u

  日期：2001.1.1

  restricted carbamates 7, 10, 11, and 15 undergo lithiation via complexes more efficiently than Boc amines 4-6. These results along with semiempirical calculations suggest that a small dihedral angle and a calculated distance of 2.78 A between the carbamate carbonyl oxygen and the proton to be removed are favorable for a carbamate-directed lithiation. A series of tin-lithium exchange experiments on

  已经研究了一系列选定的双环氨基甲酸酯，其中羰基和在 α-锂化反应中去除的质子之间的可及角度和距离在结构上被定义。恶唑烷酮 7-10 经历立体选择性锂化取代反应以提供 cis-18-27 和 cis-31-35 作为主要的非对映异构体。两个系列的竞争实验表明，构象受限的氨基甲酸酯 7、10、11 和 15 比 Boc 胺 4-6 更有效地通过复合物进行锂化。这些结果以及半经验计算表明，氨基甲酸酯羰基氧和要去除的质子之间的小二面角和 2.78 的计算距离有利于氨基甲酸酯导向的锂化。